Product
CT1812
Aliases
Active Comparator CT1812, Study Drug Active
8 clinical trials
4 indications
Indication
Dementia with Lewy BodiesIndication
Age-related macular degenerationIndication
Alzheimer's DiseaseIndication
Alzheimer's diseaseClinical trial
A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).Status: Recruiting, Estimated PCD: 2027-07-15
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C] CT1812 in Healthy Adult Male SubjectsStatus: Completed, Estimated PCD: 2022-01-17
Clinical trial
A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's DiseaseStatus: Completed, Estimated PCD: 2020-10-16
Clinical trial
A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer's DiseaseStatus: Completed, Estimated PCD: 2023-04-26
Clinical trial
A Phase 1 Study to Assess the Pharmacokinetics of Different Multiple Dose Regimens of CT1812 in Older Healthy VolunteersStatus: Completed, Estimated PCD: 2022-06-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.Status: Active (not recruiting), Estimated PCD: 2024-07-26